Calydon Capital
Source: SEC Form 13F · as of Mar 2026Calydon Capital holds 13 biotech & pharma companies tracked by BioSniper, totaling $45.3M in value as of Mar 2026 (SEC Form 13F).
Companies held
13
Total value held
$45.3M
| Company | Shares | Value |
|---|---|---|
| JNJJOHNSON & JOHNSON | 37,224 | $9.1M |
| GILDGILEAD SCIENCES, INC. | 58,971 | $8.2M |
| ABBVAbbVie Inc. | 36,983 | $8.0M |
| BMYBRISTOL MYERS SQUIBB CO | 124,527 | $7.6M |
| AMGNAMGEN INC | 20,496 | $7.2M |
| LLYELI LILLY & Co | 1,523 | $1.4M |
| AZNASTRAZENECA PLC | 4,923 | $971K |
| VRTXVERTEX PHARMACEUTICALS INC / MA | 1,987 | $887K |
| NVSNovartis AG | 5,806 | $887K |
| MRKMerck & Co., Inc. | 2,728 | $328K |
| PMPhilip Morris International Inc | 1,526 | $252K |
| GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares) | 3,996 | $221K |
| NVONovo Nordisk A/S | 5,657 | $208K |
13F holdings reflect long positions in U.S.-listed securities as reported to the SEC. Values are point-in-time for the most recent reported quarter.